We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Sanofi's Wayrilz Gets Orphan Drug Tag for IgG4-Related Disease in Japan
Read MoreHide Full Article
Key Takeaways
Sanofi secured Japan orphan drug status for Waylirz to treat IgG4-related disease.
The tag offers incentives like priority review and tax benefits to aid development.
Sanofi is studying Waylirz in late-stage studies for IgG4-RD and other rare diseases.
Sanofi (SNY - Free Report) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to Waylirz (rilzabrutinib) for the treatment of IgG4-related disease (IgG4-RD). The drug is not yet approved for this indication in any market.
How Does the Orphan Tag Benefit Sanofi’s Drug Development?
Orphan drug designation is granted by the MHLW to therapies intended for the treatment of rare diseases or conditions affecting fewer than 50,000 people in Japan. The goal is to encourage drug development for rare diseases or conditions by offering incentives such as priority consultation and guidance, preferential tax treatment, subsidies and priority review.
For Sanofi, this designation provides Waylirz with important regulatory and financial advantages as it advances through clinical development for IgG4-RD, a rare disease affecting nearly any organ and may lead to progressive organ damage if left untreated. The orphan drug designation may help accelerate progress and reduce the development burden as Sanofi works to address this critical unmet need.
This marks the third orphan drug designation for rilzabrutinib in IgG4-RD, following similar designations previously granted in the United States and the European Union.
More on Sanofi’s Waylirz
A novel BTK inhibitor, Waylirz, is designed to treat several rare immune-mediated or inflammatory diseases by restoring immune balance via multi-immune modulation. The drug is currently approved for immune thrombocytopenia (ITP) in the United States and the European Union. A regulatory filing for a similar indication is under review in Japan.
The orphan drug designation granted by MHLW to Waylirz for the IgG4-RD indication was supported by positive data from a mid-stage study. Data from this study showed that 52-week treatment reduced disease flares and other disease markers and minimized the need for treatment with glucocorticoids.
Sanofi is currently evaluating Waylirz in late-stage studies for IgG4-RD, sickle cell disease (SCD) and warm autoimmune hemolytic anemia (wAIHA). The drug is being evaluated in mid-stage studies for asthma and chronic spontaneous urticaria (CSU).
Waylirz Faces Competition in Targeted Markets
The Sanofi drug faces competition across several of its targeted indications, although the competitive intensity varies by disease area and development stage.
In the already approved ITP indication, the drug competes with Amgen’s (AMGN - Free Report) Nplate and Rigel Pharmaceuticals’ (RIGL - Free Report) Tavalisse. Though both the AMGN and RIGL drugs are built on different mechanisms, they pose a significant threat to Wayrilz that is a more recent entrant in the market.
Concerning IgG4-RD, Waylirz, if approved, may face competition from already approved therapies like Amgen’s Uplizna.
With regard to CSU, the drug would compete with the blockbuster drug Dupixent, marketed jointly by Sanofi and Regeneron, which has a strong clinical profile and significant market share across several immunology indications.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Sanofi's Wayrilz Gets Orphan Drug Tag for IgG4-Related Disease in Japan
Key Takeaways
Sanofi (SNY - Free Report) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to Waylirz (rilzabrutinib) for the treatment of IgG4-related disease (IgG4-RD). The drug is not yet approved for this indication in any market.
How Does the Orphan Tag Benefit Sanofi’s Drug Development?
Orphan drug designation is granted by the MHLW to therapies intended for the treatment of rare diseases or conditions affecting fewer than 50,000 people in Japan. The goal is to encourage drug development for rare diseases or conditions by offering incentives such as priority consultation and guidance, preferential tax treatment, subsidies and priority review.
For Sanofi, this designation provides Waylirz with important regulatory and financial advantages as it advances through clinical development for IgG4-RD, a rare disease affecting nearly any organ and may lead to progressive organ damage if left untreated. The orphan drug designation may help accelerate progress and reduce the development burden as Sanofi works to address this critical unmet need.
This marks the third orphan drug designation for rilzabrutinib in IgG4-RD, following similar designations previously granted in the United States and the European Union.
More on Sanofi’s Waylirz
A novel BTK inhibitor, Waylirz, is designed to treat several rare immune-mediated or inflammatory diseases by restoring immune balance via multi-immune modulation. The drug is currently approved for immune thrombocytopenia (ITP) in the United States and the European Union. A regulatory filing for a similar indication is under review in Japan.
The orphan drug designation granted by MHLW to Waylirz for the IgG4-RD indication was supported by positive data from a mid-stage study. Data from this study showed that 52-week treatment reduced disease flares and other disease markers and minimized the need for treatment with glucocorticoids.
Sanofi is currently evaluating Waylirz in late-stage studies for IgG4-RD, sickle cell disease (SCD) and warm autoimmune hemolytic anemia (wAIHA). The drug is being evaluated in mid-stage studies for asthma and chronic spontaneous urticaria (CSU).
Waylirz Faces Competition in Targeted Markets
The Sanofi drug faces competition across several of its targeted indications, although the competitive intensity varies by disease area and development stage.
In the already approved ITP indication, the drug competes with Amgen’s (AMGN - Free Report) Nplate and Rigel Pharmaceuticals’ (RIGL - Free Report) Tavalisse. Though both the AMGN and RIGL drugs are built on different mechanisms, they pose a significant threat to Wayrilz that is a more recent entrant in the market.
Concerning IgG4-RD, Waylirz, if approved, may face competition from already approved therapies like Amgen’s Uplizna.
With regard to CSU, the drug would compete with the blockbuster drug Dupixent, marketed jointly by Sanofi and Regeneron, which has a strong clinical profile and significant market share across several immunology indications.